[Changes in the treatment of metastatic prostate cancer-new data and open questions].
Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen.
Androgen receptor
Chemotherapy
Oligometastases
Prostatic neoplasms, castration-naive
Systemic therapy
Journal
Der Urologe. Ausg. A
ISSN: 1433-0563
Titre abrégé: Urologe A
Pays: Germany
ID NLM: 1304110
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
30
11
2019
medline:
19
3
2020
entrez:
30
11
2019
Statut:
ppublish
Résumé
The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.
Identifiants
pubmed: 31781782
doi: 10.1007/s00120-019-01072-0
pii: 10.1007/s00120-019-01072-0
doi:
Substances chimiques
Androgen Antagonists
0
Antineoplastic Agents, Hormonal
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
307-317Références
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Crit Rev Oncol Hematol. 2015 Dec;96(3):498-506
pubmed: 26318091
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
J Clin Oncol. 2016 Aug 20;34(24):2835-42
pubmed: 27325855
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Eur Urol. 2014 Jun;65(6):1058-66
pubmed: 24290503
Urologe A. 2018 Jul;57(7):813-820
pubmed: 29808368
Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85
pubmed: 25606573
Eur Urol. 2017 Sep;72(3):345-351
pubmed: 28416350
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Eur Urol. 2018 May;73(5):696-703
pubmed: 29074061
Lancet Oncol. 2013 Feb;14(2):117-24
pubmed: 23294853
J Clin Oncol. 2014 Oct 20;32(30):3383-90
pubmed: 25225419
Eur Urol Focus. 2017 Dec;3(6):646-649
pubmed: 28753877
Clin Genitourin Cancer. 2018 Aug;16(4):e777-e784
pubmed: 29550200
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
J Clin Oncol. 2013 Oct 20;31(30):3800-6
pubmed: 24043751
Eur Urol. 2014 Sep;66(3):602-3
pubmed: 24821581
Eur Urol. 2014 Feb;65(2):270-273
pubmed: 24295792
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Crit Rev Oncol Hematol. 2016 Apr;100:127-36
pubmed: 26363809